NASDAQ:EVLO Evelo Biosciences - EVLO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Evelo Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.25 -0.01 (-3.85%) (As of 03/20/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.24▼$0.2850-Day Range$0.25▼$1.4052-Week Range$0.24▼$4.36Volume162,955 shsAverage Volume165,290 shsMarket Capitalization$27.00 millionP/E RatioN/ADividend YieldN/APrice Target$3.17 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Evelo Biosciences MarketRank™ ForecastAnalyst RatingHold1.75 Rating ScoreUpside/Downside1,166.7% Upside$3.17 Price TargetShort InterestHealthy2.54% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.12Based on 7 Articles This WeekInsider TradingSelling Shares$160 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.92) to ($0.95) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.82 out of 5 starsMedical Sector732nd out of 988 stocksPharmaceutical Preparations Industry352nd out of 482 stocks 2.9 Analyst's Opinion Consensus RatingEvelo Biosciences has received a consensus rating of Hold. The company's average rating score is 1.75, and is based on no buy ratings, 3 hold ratings, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $3.17, Evelo Biosciences has a forecasted upside of 1,166.7% from its current price of $0.25.Amount of Analyst CoverageEvelo Biosciences has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.54% of the outstanding shares of Evelo Biosciences have been sold short.Short Interest Ratio / Days to CoverEvelo Biosciences has a short interest ratio ("days to cover") of 20.7, which indicates bearish sentiment.Change versus previous monthShort interest in Evelo Biosciences has recently decreased by 22.16%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldEvelo Biosciences does not currently pay a dividend.Dividend GrowthEvelo Biosciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for EVLO. Previous Next 2.3 News and Social Media Coverage News SentimentEvelo Biosciences has a news sentiment score of 0.12. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.35 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Evelo Biosciences this week, compared to 1 article on an average week.Search InterestOnly 9 people have searched for EVLO on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows1 people have added Evelo Biosciences to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Evelo Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $160.00 in company stock.Percentage Held by InsidersOnly 8.20% of the stock of Evelo Biosciences is held by insiders.Percentage Held by Institutions85.31% of the stock of Evelo Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Evelo Biosciences are expected to decrease in the coming year, from ($0.92) to ($0.95) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evelo Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evelo Biosciences is -0.17, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioEvelo Biosciences has a P/B Ratio of 1.56. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Evelo Biosciences (NASDAQ:EVLO) StockEvelo Biosciences, Inc. operates as a clinical stage biotechnology company, which engages in the development of orally delivered investigational medicines. Its portfolio includes EDP1066 and EDP1815 for the treatment of inflammatory diseases, EDP2939 for inflammation, and EDP1908 for oncology. The company was founded by Noubar B. Afeyan and David A. Berry in 2014 and is headquartered in Cambridge, MA.Read More Receive EVLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EVLO Stock News HeadlinesMarch 20, 2023 | americanbankingnews.comEvelo Biosciences (NASDAQ:EVLO) Price Target Cut to $5.00 by Analysts at BMO Capital MarketsMarch 18, 2023 | seekingalpha.comEvelo Biosciences, Inc. (EVLO) Q4 2022 Earnings Call TranscriptMarch 21, 2023 | Legacy Research (Affiliate) (Ad)"Prepare for Five Years of Famine"Market Wizard who predicted all indexes would be negative in 2022 shares shocking new forecastMarch 16, 2023 | finance.yahoo.comEvelo Biosciences Announces Fourth Quarter and Full Year 2022 Financial Results and Business HighlightsMarch 15, 2023 | msn.comEarnings Preview: Evelo BiosciencesMarch 9, 2023 | finance.yahoo.comEvelo Biosciences to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 16, 2023March 1, 2023 | finance.yahoo.comAfter Plunging -40.39% in 4 Weeks, Here's Why the Trend Might Reverse for Evelo Biosciences, Inc. (EVLO)March 1, 2023 | finance.yahoo.comEvelo Biosciences to Participate in the Cowen 43rd Annual Health Care ConferenceMarch 21, 2023 | Weiss Ratings (Ad)Fed's Shocking New Plan to Control Your MoneyThe Federal Reserve has a disturbing plan that is getting ready to roll out as soon as May. This is a lot more than printing trillions of dollars or manipulating interest rates. It's about every checking account, every purchase and every money transfer in America — including yours and mine. February 27, 2023 | finance.yahoo.comEvelo Biosciences Reports that EDP2939, its First Oral Extracellular Vesicle Product Candidate, Commenced Dosing in a Phase 2 Psoriasis TrialFebruary 13, 2023 | finance.yahoo.comDown -39.46% in 4 Weeks, Here's Why Evelo Biosciences, Inc. (EVLO) Looks Ripe for a TurnaroundFebruary 1, 2023 | msn.comWhy WestRock Company Are Trading Lower By 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day SessionFebruary 1, 2023 | msn.comEvelo Biosciences sheds 48 employees after skin disease treatment failsFebruary 1, 2023 | finance.yahoo.comEvelo Biosciences' Atopic Dermatitis Study Fails, Observes Unusually High Placebo Response RatesFebruary 1, 2023 | finance.yahoo.comFlagship-backed biotech cuts nearly half its staffFebruary 1, 2023 | msn.comEvelo drops 23% as atopic dermatitis trial fails; announces layoffsFebruary 1, 2023 | reuters.comEvelo Biosciences to cut jobs, skin disease drug trial disappointsFebruary 1, 2023 | finance.yahoo.comEvelo Biosciences Provides Clinical and Business UpdatesFebruary 1, 2023 | finance.yahoo.comUPDATE 1-Evelo Biosciences to cut jobs, skin disease drug trial disappointsJanuary 11, 2023 | finance.yahoo.comHorizon Technology Finance Provides Fourth Quarter 2022 Portfolio UpdateDecember 14, 2022 | finance.yahoo.comSenda Biosciences Appoints MIT Institute Professor Paula Hammond, Ph.D., to Its Board of DirectorsDecember 1, 2022 | finance.yahoo.comEvelo Biosciences, Inc. (NASDAQ:EVLO) insiders placed bullish bets worth US$575k in the last 12 monthsNovember 15, 2022 | finanznachrichten.deEvelo Biosciences, Inc.: Evelo Biosciences Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 15, 2022 | finance.yahoo.comEvelo Biosciences Announces Publication of Scientific Basis for SINTAX Medicines in Frontiers in ImmunologyNovember 15, 2022 | finance.yahoo.comEvelo Biosciences Reports Third Quarter 2022 Financial Results and Business HighlightsNovember 8, 2022 | finance.yahoo.comEvelo Biosciences to Present at the 2022 Jefferies London Healthcare ConferenceSeptember 7, 2022 | finance.yahoo.comEvelo Biosciences Presents Biomarker Data Demonstrating Anti-inflammatory Effects of EDP1815 in Psoriasis at the 2022 European Academy of Dermatology and Venereology (EADV) CongressSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive EVLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evelo Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address EVLO Company Calendar Last Earnings10/27/2021Today3/20/2023Next Earnings (Estimated)5/11/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:EVLO CUSIPN/A CIK1694665 Webwww.evelobio.com Phone(617) 577-0300FaxN/AEmployees122Year FoundedN/APrice Target and Rating Average Stock Price Forecast$3.17 High Stock Price Forecast$5.00 Low Stock Price Forecast$2.00 Forecasted Upside/Downside+1,166.7%Consensus RatingHold Rating Score (0-4)1.75 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-122,180,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-1,219.24% Return on Assets-133.66% Debt Debt-to-Equity Ratio3.93 Current Ratio2.69 Quick Ratio2.69 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.16 per share Price / Book1.56Miscellaneous Outstanding Shares107,990,000Free Float99,138,000Market Cap$27.00 million OptionableNot Optionable Beta1.37 Key ExecutivesSimba GillPresident, Chief Executive Officer & DirectorAnn Marella ThorellChief Financial Officer, Treasurer & Senior VPMark W. BodmerChief Scientific Officer, President-R&DAndrea ItanoSenior Vice President & Head-ResearchDuncan McHaleChief Medical OfficerKey CompetitorsMonopar TherapeuticsNASDAQ:MNPRKala PharmaceuticalsNASDAQ:KALAAcer TherapeuticsNASDAQ:ACERTherapeuticsMDNASDAQ:TXMDCorvus PharmaceuticalsNASDAQ:CRVSView All CompetitorsInsiders & InstitutionsMillennium Management LLCSold 90,822 shares on 2/15/2023Ownership: 0.087%Morgan StanleyBought 14,567 shares on 2/15/2023Ownership: 0.073%Boothbay Fund Management LLCBought 52,699 shares on 2/15/2023Ownership: 0.049%Man Group plcBought 52,637 shares on 2/15/2023Ownership: 0.049%Shay Capital LLCBought 18,511 shares on 2/15/2023Ownership: 0.017%View All Insider TransactionsView All Institutional Transactions EVLO Stock - Frequently Asked Questions Should I buy or sell Evelo Biosciences stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evelo Biosciences in the last year. There are currently 1 sell rating and 3 hold ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" EVLO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EVLO, but not buy additional shares or sell existing shares. View EVLO analyst ratings or view top-rated stocks. What is Evelo Biosciences' stock price forecast for 2023? 4 equities research analysts have issued 12-month price targets for Evelo Biosciences' shares. Their EVLO share price forecasts range from $2.00 to $5.00. On average, they anticipate the company's share price to reach $3.17 in the next year. This suggests a possible upside of 1,166.7% from the stock's current price. View analysts price targets for EVLO or view top-rated stocks among Wall Street analysts. How have EVLO shares performed in 2023? Evelo Biosciences' stock was trading at $1.61 at the beginning of the year. Since then, EVLO stock has decreased by 84.5% and is now trading at $0.25. View the best growth stocks for 2023 here. Are investors shorting Evelo Biosciences? Evelo Biosciences saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 2,740,000 shares, a decrease of 22.2% from the February 13th total of 3,520,000 shares. Based on an average trading volume of 132,200 shares, the short-interest ratio is currently 20.7 days. View Evelo Biosciences' Short Interest. When is Evelo Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 11th 2023. View our EVLO earnings forecast. How were Evelo Biosciences' earnings last quarter? Evelo Biosciences, Inc. (NASDAQ:EVLO) issued its quarterly earnings data on Wednesday, October, 27th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.54) by $0.09. During the same period in the prior year, the company posted ($0.45) earnings per share. What other stocks do shareholders of Evelo Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Evelo Biosciences investors own include Fulcrum Therapeutics (FULC), VIVUS (VVUS), Evofem Biosciences (EVFM), Sorrento Therapeutics (SRNE), Cerecor (CERC), Myovant Sciences (MYOV), Provention Bio (PRVB), VBI Vaccines (VBIV), VYNE Therapeutics (VYNE) and Aldeyra Therapeutics (ALDX). When did Evelo Biosciences IPO? (EVLO) raised $85 million in an initial public offering on Wednesday, May 9th 2018. The company issued 5,300,000 shares at $15.00-$17.00 per share. Morgan Stanley, Cowen and BMO Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager. What is Evelo Biosciences' stock symbol? Evelo Biosciences trades on the NASDAQ under the ticker symbol "EVLO." Who are Evelo Biosciences' major shareholders? Evelo Biosciences' stock is owned by many different institutional and retail investors. Top institutional shareholders include Geode Capital Management LLC (0.56%), Mayo Clinic (0.44%), Mayo Clinic (0.44%), Susquehanna International Group LLP (0.14%), Trustees of Columbia University in the City of New York (0.11%) and Citigroup Inc. (0.09%). Insiders that own company stock include David R Epstein, Stephen J Carriere, Ventures Fund Iv Gene Flagship and Xiaoli Jacqueline Liu. View institutional ownership trends. How do I buy shares of Evelo Biosciences? Shares of EVLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Evelo Biosciences' stock price today? One share of EVLO stock can currently be purchased for approximately $0.25. How much money does Evelo Biosciences make? Evelo Biosciences (NASDAQ:EVLO) has a market capitalization of $27.00 million. The company earns $-122,180,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. How many employees does Evelo Biosciences have? The company employs 122 workers across the globe. How can I contact Evelo Biosciences? Evelo Biosciences' mailing address is 620 Memorial Drive Suite 500 West, Cambridge MA, 02139. The official website for the company is www.evelobio.com. The company can be reached via phone at (617) 577-0300 or via email at ir@evelobio.com. This page (NASDAQ:EVLO) was last updated on 3/21/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.